Buttercup Bronchostop Berry Flavour Cough Pastilles
*Company:
Chefaro Ireland DACStatus:
No Recent UpdateLegal Category:
Supply through general saleActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Summary of Product Characteristics last updated on medicines.ie:25/6/2015 Print View
Buttercup Bronchostop Berry Flavour Cough Pastilles
Each pastille contains:
59.5 mg of dry extract from Thymus vulgaris L. and Thymus zygis L., herba (Thyme herb) (DER 7-13:1) Extraction solvent: water
Excipients with known effect:
Each pastille contains 300 mg of fructose and 523 mg of sorbitol (E420).
For the full list of excipients, see section 6.1
Pastille.
Hexagonal, brown pastilles with a fruity taste.
4.1 Therapeutic indications
Traditional herbal medicinal product used for the relief of coughs, such as chesty, dry, tickly, irritating coughs and catarrh exclusively based on long standing use.
4.2 Posology and method of administration
For oral short-term use only.
Adults, the elderly and children over 12 years:
1 – 2 pastilles to be taken every 4 hours, 4 times a day. If required, up to a maximum of 12 pastilles can be taken per day.
Method of administration:
For oral use (allow to dissolve in the mouth through sucking).
This product is not recommended for use in children under 12 years of age (See 'Section 4.4 Special warnings and precautions for use.')
Duration of use:
If symptoms worsen, or persist after 7 days, a doctor or a qualified Healthcare Professional e.g. a doctor or pharmacist should be consulted.
4.3 Contraindications
Hypersensitivity to thyme or to other members of the Lamiaceae family, or to any of the excipients (listed in section 6.1).
4.4 Special warnings and precautions for use
Do not exceed the stated dose.
The use in children under 12 years of age is not recommended due to lack of data and because medical advice should be sought.
If symptoms worsen, or persist after 7 days, a doctor or qualified Healthcare Professional should be consulted.
If dyspnoea, fever or purulent sputum occurs, a doctor or qualified Healthcare Professional should be consulted.
Contains 0.6 g of fructose per maximum single dose (2 pastilles). This should be taken into account in patients with diabetes mellitus.
Contains fructose and sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.
4.6 Fertility, pregnancy and lactation
The safety of the product during pregnancy and lactation has not been established. Therefore, in the absence of sufficient data, use during pregnancy and lactation is not recommended.
Studies on the effects on fertility have not been performed.
4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and to use machines have been performed.
4.8 Undesirable effects
Hypersensitivity reactions (including one case of anaphylactic shock and one case of Quincke's edema) as well as stomach disorders have been observed in connection with medicinal products containing thyme. The frequency is not known.
If other adverse reactions not mentioned above occur, a qualified Healthcare Professional e.g. a doctor or pharmacist should be consulted.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare Professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.
4.9 Overdose
No case of overdose has been reported.
5.1 Pharmacodynamic properties
Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.
5.2 Pharmacokinetic properties
Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended
5.3 Preclinical safety data
Tests on genotoxicity have been performed with different thyme herb extracts and thyme essential oil. No mutagenicity was observed in the Ames tests conducted.
Tests on reproductive toxicity and carcinogenicity have not been performed.
6.1 List of excipients
Herbal Preparation:
Maltodextrin
Acacia
Pastille:
Acacia
Fructose
Sorbitol (E420)
Anhydrous Citric Acid
Saccharin Sodium
Aronia (chokeberry) aroma flavour
Fruit of the forest (berry) aroma flavour
Light Liquid Paraffin
White Beeswax
Purified Water
6.2 Incompatibilities
Not applicable
6.3 Shelf life
3 years
6.4 Special precautions for storage
Do not store above 30°C. Store the blister in the original package in order to protect from light.
6.5 Nature and contents of container
Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
No special requirements
Kwizda Pharma GmbH
Effingergasse 21
1160 Vienna
Austria
TR2006/001/002
Date of first Authoristation: 13 March 2015